Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

Biogen (NASDAQ:BIIB – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $220.00 to ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $173.52 which represents a decrease of $-0.27 or -0.16% from the prior close of $173.79. The stock opened at $173.22 and touched a ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling. Meanwhile, some companies such as Biogen, U.S. Bancorp ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB.

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...